Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

The definition of tuberculosis infection based on the spectrum of tuberculosis disease

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Latent Mycobacterium tuberculosis infection.

Incipient tuberculosis: a comprehensive overview

Current Concepts in the Management of Tuberculosis

New developments in tuberculosis diagnosis and treatment

Diagnosis and treatment of latent infection with Mycobacterium tuberculosis.

Advances in Understanding Immune Homeostasis in Latent Tuberculosis Infection.

A modern view on the mechanism of occurrence and development of latent tuberculosis infection. Literature review

Tuberculosis: Current state of knowledge: An Epilogue

Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches

Spotting the Old Foe-Revisiting the Case Definition for TB.

The past, present and future of tuberculosis treatment.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children

Assessing infectiousness and the impact of effective treatment to guide isolation recommendations for people with pulmonary tuberculosis

A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes

Current landscape of exosomes in tuberculosis development, diagnosis, and treatment applications

Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis

Heterogeneity in tuberculosis

Editorial: Factors for the Progression from Latent Tuberculosis Infection to Tuberculosis Disease